Microphthalmia

Microphthalmia is a congenital anomaly marked by unusually small eyes, frequently resulting in substantial visual impairment. As a distinguished research services company, Protheragen is dedicated to delivering expert microphthalmia diagnostics and innovative therapeutic development solutions.

Overview of Microphthalmia

Microphthalmia is a congenital ocular condition characterized by the underdevelopment of the eye, presenting as an eye that is smaller than the normal population mean. This condition can range from mild microphthalmia, where the eye is merely smaller, to severe cases, where the eye is significantly reduced or even absent (anophthalmia). The impact on vision is variable and depends on the extent of the eye's development and associated ocular abnormalities.

Fig.1 The genetics of optic cup and lens formation. (Harding P., et al., 2019)

Genetic Basis of Microphthalmia

From a scientific perspective, microphthalmia is underpinned by a complex genetic architecture. Over 90 genes have been implicated in the development of this condition, reflecting its genetic heterogeneity. Key genes associated with microphthalmia include SOX2, OTX2, RAX, VSX2, and PAX6, which play crucial roles in the orchestration of eye development. Mutations in these genes can lead to the disrupted formation and differentiation of ocular structures, resulting in the phenotypes observed in microphthalmia.

Table 1. Genes associated with anophthalmia and microphthalmia. (Harding P., et al., 2019)

Diagnostics Development for Microphthalmia

Molecular Diagnostics

The genetic basis of microphthalmia is complex and heterogeneous, with over 90 identified genes associated with the condition. Molecular diagnostics play a crucial role in identifying the genetic underpinnings of microphthalmia. High-throughput next-generation sequencing (NGS) technologies have revolutionized the field, allowing for the identification of pathogenic variants in known genes such as SOX2, OTX2, and PAX6, which are crucial for normal eye development.

Therapeutics Development for Microphthalmia

Our Services

With a cutting-edge team and platform, Protheragen is at the forefront of therapeutic innovation, leveraging extensive expertise in genetic and molecular research to provide clients with specialized microphthalmia diagnostics and therapeutic development services.

Target Validation & Mechanistic Characterization Services

Protheragen supports clients in validating novel therapeutic targets for microphthalmia using molecular, cellular, and pathway‑focused assays. This service includes genetic perturbation studies (CRISPR‑mediated knockout, knockdown, or overexpression) in human pluripotent stem cell (hPSC) derived ocular progenitor cells to assess the role of specific genes or variants in optic vesicle growth, lens induction, retinal layer formation, and optic nerve development. Pathway analysis services quantify activity in WNT, BMP, SHH, retinoic acid, and other developmental cascades linked to microphthalmia, using reporter assays, transcriptomic profiling (RNA‑seq), and proteomic analysis to map dysregulated signaling networks.

Additional mechanistic services include phenotypic rescue assays to confirm that target modulation restores normal ocular developmental patterns. Protheragen also provides bioinformatic analysis to integrate client genomic data with known microphthalmia‑associated loci, identifying actionable targets for therapeutic intervention. These services are critical for establishing target druggability and justifying further investment in lead discovery.

In Vitro Model Systems & Disease Modeling Services

Protheragen offers a suite of human‑relevant in vitro microphthalmia disease models to recapitulate key pathological features without animal or clinical exposure. Core models include:

• hPSC‑derived optic vesicle and optic cup organoids: 3D self‑assembling ocular structures that mimic early human eye development, allowing visualization of morphogenetic defects, tissue hypoplasia, and structural abnormalities seen in microphthalmia. Genetic editing can generate isogenic mutant organoids carrying patient‑derived variants for personalized disease modeling.
• Ocular progenitor cell proliferation and differentiation assays: 2D cultures of retinal progenitor cells, corneal epithelial cells, lens epithelial cells, and optic nerve glia to measure cell survival, proliferation rate, differentiation efficiency, and maturation status under developmental stress or genetic perturbation.
• High‑content imaging (HCI) platforms: Automated quantitative microscopy to measure ocular structure size, tissue morphology, cell number, layer organization, and marker expression in organoid and 2D systems, providing unbiased phenotypic metrics for drug response.

These models enable clients to recapitulate microphthalmic phenotypes in a controlled, scalable laboratory setting, supporting high‑throughput testing and mechanistic studies without animal use.

Drug Screening & Lead Optimization Services

For small molecules, peptide therapeutics, and biologics, Protheragen provides targeted and phenotypic screening services tailored to microphthalmia. High‑throughput screening (HTS) assays measure rescue of developmental defects—including restoration of optic vesicle size, improved cell survival, enhanced differentiation, and normalized signaling activity—in 2D and 3D ocular models. Dose‑response profiling determines EC50, IC50, and maximal efficacy for lead compounds, while structure‑activity relationship (SAR) analysis supports medicinal chemistry optimization.

Additional lead optimization services include:

• Solubility, stability, and ocular compatibility testing
• Cellular uptake and intracellular distribution analysis in ocular cell types
• Selectivity profiling against off‑target developmental pathways
• Long‑term maturation assessment to confirm sustained developmental rescue

This service package accelerates the identification of potent, selective, and developmentally active lead candidates for microphthalmia.

Gene Therapy Development & Vector Characterization Services

Protheragen supports preclinical gene therapy development for genetic forms of microphthalmia, focusing on vector design, expression efficacy, and biological activity in ocular models. Services include:

• Gene vector activity assays: Evaluation of AAV, lentiviral, and non‑viral vectors for tropism, transduction efficiency, and transgene expression in human ocular progenitor cells and organoids.
• Gene replacement & editing validation: Assessment of functional rescue in mutant ocular models via wild‑type gene replacement, CRISPR‑based gene correction, or allele‑specific silencing.
• Expression cassette optimization: Analysis of promoter strength, tissue specificity, and duration of transgene expression in developing ocular tissues.
• Vector safety profiling: Assessment of genotoxicity, inflammatory activation, and off‑target editing in ocular cell systems.

These services enable clients to engineer safe, effective, tissue‑targeted gene therapies for monogenic microphthalmia.

Ocular Toxicology & Safety Pharmacology Services

Protheragen provides specialized in vitro ocular toxicology services to evaluate the safety of microphthalmia drug candidates during early development. Services include:

• Cytotoxicity and cell viability testing in retinal, corneal, lens, and optic nerve cells
• Oxidative stress, inflammation, and apoptotic response quantification
• Developmental toxicity assessment in embryonic ocular organoids to detect interference with morphogenesis
• Histological and ultrastructural analysis of tissue integrity and cellular morphology
• Biosafety profiling of gene vectors and cell preparations for immunogenicity and integration risk

All toxicology studies use human ocular cell types and 3D organoids to provide species‑relevant safety data, reducing reliance on animal models and improving clinical translatability.

Quantitative Analytical & Bioanalytical Services

To support rigorous data interpretation, Protheragen offers quantitative analytical services for microphthalmia research:

• Gene expression analysis (qPCR, RNA‑seq) for developmental and therapeutic response markers
• Protein quantification (Western blot, ELISA, immunofluorescence quantification)
• Morphometric analysis of ocular structure size, shape, and tissue volume
• Biomarker discovery and validation for developmental rescue and disease progression
• Statistical analysis and regulatory‑style report preparation

These services ensure that client data is quantitative, reproducible, and publication‑ready.

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein

Preclinical Research

• Pharmacodynamics Study Services
• Pharmacokinetics Study Services
• Drug Safety Evaluation Services

Disease Models

• SOX2 Mutant Mouse Models
• OTX2 Mutant Mouse Models
• RAX Mutant Mouse Models
• VSX2 Mutant Mouse Models
• PAX6 Mutant Mouse Models
• rx3 Mutant Zebrafish Models
• pax6 Mutant Zebrafish Models

Leveraging the forefront of stem cell technology, we are dedicated to investigating and addressing microphthalmia. Our focus is on harnessing the capabilities of induced pluripotent stem cells (iPSCs) to not only model the disease but also to pave the way for regenerative therapies aimed at restoring normal visual functions.

Furthermore, we excel in offering an extensive array of preclinical research services, which are crucial for the advancement of potent microphthalmia therapeutics. Our services include critical assessments such as pharmacokinetic and toxicology studies, ensuring the efficacy and safety of these therapeutics. If you are interested in our services, please feel free to contact us.

References

• Harding, Philippa, and Mariya Moosajee. "The molecular basis of human anophthalmia and microphthalmia." Journal of developmental biology 7.3 (2019): 16.
• Plaisancie, Julie, Patrick Calvas, and Nicolas Chassaing. "Genetic advances in microphthalmia." Journal of pediatric genetics 5.04 (2016): 184-188.